Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

9
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
9
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

15
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

346
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
346
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

400
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
400
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

14
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating metabolomic and lipidomic profiles distinguish patients with acute heart failure de novo vs. worsening of heart failure.

Polish archives of internal medicine·2026
Same author

Worsening renal function in acute heart failure: a hemoconcentration-conditioned interpretation with ranges of benefit, safety, and harm.

Revista espanola de cardiologia (English ed.)·2026
Same author

A Machine-Learning Model for Accurate Diuresis Prediction in Acute Heart Failure (DRC-AHF).

ESC heart failure·2026
Same author

A Contemporary Perspective on Acute Decompensated Heart Failure Classification: A State-of-the-art Review from an International Expert Group.

Cardiac failure review·2026
Same author

Acute Myocardial Infarction versus Acute Decompensated Heart Failure in Cardiogenic Shock: A Systematic Review and Meta-Analysis of Clinical Phenotypes and Mortality.

European journal of heart failure·2026
Same author

Contemporary Management of Acute Heart Failure: From Emergency Presentation to Long-Term Remission.

Journal of the American College of Cardiology·2026

Related Experiment Video

Updated: Jul 11, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K

Preload Reduction Therapies in Heart Failure.

Muhammad Shahzeb Khan1, Anousheh Awais Paracha2, Jan Biegus3

  • 1Division of Cardiology, Department of Medicine, Duke University, Durham, NC, USA.

Heart Failure Clinics
|November 12, 2023
PubMed
Summary

Preload reduction strategies are crucial for managing heart failure (HF). This review explores splanchnic nerve modulation, pharmacology, and devices to prevent HF decompensation by reducing cardiac preload.

Keywords:
CongestionHeart failurePreloadStressed blood volumeUnstressed blood volume

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.3K
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

766

Related Experiment Videos

Last Updated: Jul 11, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.3K
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

766

Area of Science:

  • Cardiology
  • Physiology

Background:

  • Preload reserve is vital for healthy cardiac function, increasing blood volume and cardiac output.
  • In heart failure (HF), increased preload can worsen decompensation.
  • Understanding preload's role is key to managing HF patients.

Purpose of the Study:

  • To review methods for preventing heart failure decompensation via preload reduction.
  • To explore splanchnic nerve modulation, pharmacological, and device-based interventions.

Main Methods:

  • Literature review focusing on preload reduction in heart failure.
  • Analysis of therapeutic interventions targeting splanchnic nerve and cardiac preload.
  • Examination of ongoing clinical trials for device-based approaches.

Main Results:

  • Splanchnic nerve modulation and specific pharmacological agents can reduce preload.
  • Device-based therapies are emerging as novel approaches for preload management.
  • Clinical trials are evaluating the efficacy of these interventions.

Conclusions:

  • Targeting preload reduction is a promising strategy for managing heart failure.
  • A combination of pharmacological and device-based interventions may offer new therapeutic avenues.
  • Further research and clinical trials are essential to optimize preload management in HF.